ArticleInfection2014
SIMIFF study: Italian fungal registry of mold infections in hematological and non-hematological patients.
Article in Infection, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Article
- Invasive Fusariosis Among Patients with Acute Leukemia: A 12-Year Single-Center Experience in a Middle-Income Country.Mycopathologia · 2026Article
- Prevalence and Factors Associated WithOpen forum infectious diseases · 2026Article
- Article
- Article
- Isavuconazole as an optimal treatment option for multiple pathogens induced severe pneumonia in immunocompromised hosts: a case series report.Frontiers in medicine · 2025Article
- Central Nervous System Fungal Diseases in Children with Malignancies: A 16-Year Study from the Infection Working Group of the Hellenic Society of Pediatric Hematology Oncology.Journal of fungi (Basel, Switzerland) · 2024Article
- Clinical characteristics and outcomes of pleural aspergillosis: a review of 13 cases.Microbiology spectrum · 2024Article
- Imaging Findings in Aspergillosis: From Head to Toe.Mycopathologia · 2023Review
- Tendency in Pulmonary Aspergillosis Investigation during the COVID-19 Era: What Is Changing?International journal of environmental research and public health · 2022Article
- Therapeutic Approaches for CombatingCurrent drug targets · 2022Review
- Population Pharmacokinetics and Pharmacodynamic Target Attainment of Isavuconazole againstPharmaceutics · 2021Article
- Transcription Factor HSF1 Suppresses the Expression of Surfactant Protein D in Cells Infected withPathogens (Basel, Switzerland) · 2021Article
- Central Nervous System Mold Infections in Children with Hematological Malignancies: Advances in Diagnosis and Treatment.Journal of fungi (Basel, Switzerland) · 2021Review
- Filamentous Fungal Infections in a Tertiary Care Setting: Epidemiology and Clinical Outcome.Journal of fungi (Basel, Switzerland) · 2021Article
- Lipopolysaccharide Binding Protein and Bactericidal/Permeability-Increasing Protein as Biomarkers for Invasive Pulmonary Aspergillosis.Journal of fungi (Basel, Switzerland) · 2020Article
- Comparison of β-D-Glucan and Galactomannan in Serum for Detection of Invasive Aspergillosis: Retrospective Analysis with Focus on Early Diagnosis.Journal of fungi (Basel, Switzerland) · 2020Article
- Occurrence of Fungi in the Potable Water of Hospitals: A Public Health Threat.Pathogens (Basel, Switzerland) · 2020Article
- Positive quantitative PCR detecting Fusarium solani in a case of mixed invasive fungal disease due to Mucorales and Fusarium solani.Bone marrow transplantation · 2020Article
- Aspergillus fumigatus and Aspergillosis in 2019.Clinical microbiology reviews · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe compared the risk factors, the diagnostic tools and the outcome of filamentous fungal infections (FFIs) in hematological patients (HAEs) and non-hematological patients (non-HAEs).
methodsProspective surveillance (2009-2011) of proven and probable FFIs was implemented in 23 Italian hospitals.
resultsOut of 232 FFIs, 113 occurred in HAEs and 119 in non-HAEs. The most frequent infection was invasive aspergillosis (76.1 % for HAEs, 56.3 % for non-HAEs), and the localization was principally pulmonary (83.2 % for HAEs, 74.8 % for non-HAEs). Neutropenia was a risk factor for 89.4 % HAEs; the main underlying condition was corticosteroid treatment (52.9 %) for non-HAEs. The distribution of proven and probable FFIs was different in the two groups: proven FFIs occurred more frequently in non-HAEs, whereas probable FFIs were correlated with the HAEs. The sensitivity of the galactomannan assay was higher for HAEs than for non-HAEs (95.3 vs. 48.1 %). The overall mortality rate was 44.2 % among the HAEs and 35.3 % among the non-HAEs. The etiology influenced the patient outcomes: mucormycosis was associated with a high mortality rate (57.1 % for HAEs, 77.8 % for non-HAEs).
conclusionsThe epidemiological and clinical data for FFIs were not identical in the HAEs and non-HAEs. The differences should be considered to improve the management of FFIs according to the patients' setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.